BR112022004401A2 - Tratamento de diabetes mellitus tipo 2 - Google Patents

Tratamento de diabetes mellitus tipo 2

Info

Publication number
BR112022004401A2
BR112022004401A2 BR112022004401A BR112022004401A BR112022004401A2 BR 112022004401 A2 BR112022004401 A2 BR 112022004401A2 BR 112022004401 A BR112022004401 A BR 112022004401A BR 112022004401 A BR112022004401 A BR 112022004401A BR 112022004401 A2 BR112022004401 A2 BR 112022004401A2
Authority
BR
Brazil
Prior art keywords
type
diabetes mellitus
pharmaceutically acceptable
acceptable salt
mellitus treatment
Prior art date
Application number
BR112022004401A
Other languages
English (en)
Inventor
Elisabeth Niemoeller
Elisabeth Souhami
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112022004401A2 publication Critical patent/BR112022004401A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

folha dispersível em água. a presente invenção refere-se a uma combinação farmacêutica, que compreende (a) uma formulação farmacêutica compreendendo (i) lixisenatida e/ou um sal farmaceuticamente aceitável da mesma e (ii) insulina glargina e/ou um sal farmaceuticamente aceitável da mesma e (b) um inibidor de sglt2 e/ou um sal farmaceuticamente aceitável do mesmo.
BR112022004401A 2019-09-13 2020-09-10 Tratamento de diabetes mellitus tipo 2 BR112022004401A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306106 2019-09-13
PCT/EP2020/075304 WO2021048266A1 (en) 2019-09-13 2020-09-10 Treatment of type 2 diabetes mellitus

Publications (1)

Publication Number Publication Date
BR112022004401A2 true BR112022004401A2 (pt) 2022-05-31

Family

ID=68137978

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004401A BR112022004401A2 (pt) 2019-09-13 2020-09-10 Tratamento de diabetes mellitus tipo 2

Country Status (13)

Country Link
US (1) US20210093698A1 (pt)
EP (1) EP4028045A1 (pt)
JP (1) JP2022552455A (pt)
KR (1) KR20220062592A (pt)
CN (1) CN114423462A (pt)
AU (1) AU2020344895A1 (pt)
BR (1) BR112022004401A2 (pt)
CA (1) CA3150682A1 (pt)
CO (1) CO2022004572A2 (pt)
IL (1) IL291247A (pt)
MX (1) MX2022003096A (pt)
TW (1) TW202126288A (pt)
WO (1) WO2021048266A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117323413A (zh) * 2023-09-07 2024-01-02 中山大学附属第一医院 利拉鲁肽在治疗糖尿病相关眼病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US20120283169A1 (en) * 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN105377266A (zh) * 2013-04-18 2016-03-02 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
SG11201509781YA (en) 2013-06-17 2015-12-30 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
JP6970615B2 (ja) * 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン／リキシセナチド固定比処方

Also Published As

Publication number Publication date
KR20220062592A (ko) 2022-05-17
EP4028045A1 (en) 2022-07-20
JP2022552455A (ja) 2022-12-16
MX2022003096A (es) 2022-04-11
CN114423462A (zh) 2022-04-29
AU2020344895A1 (en) 2022-04-28
TW202126288A (zh) 2021-07-16
US20210093698A1 (en) 2021-04-01
WO2021048266A1 (en) 2021-03-18
CA3150682A1 (en) 2021-03-18
CO2022004572A2 (es) 2022-07-08
IL291247A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
BR112021023923A2 (pt) Agonistas de receptor de peptídeo 1 similares a glucagon
AR109170A2 (es) Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
CL2011001735A1 (es) Composicion farmaceutica que comprende: a) el inhibidor de sglt2 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)-bencil]-benceno, b) el inhibidor de dppiv linagliptina y c) un tercer agente antidiabetico que es clorhidrato de metformina; y su uso para tratar la diabetes mellitus tipo 2.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2023001351A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil.
BR112013004756B1 (pt) uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
BR0213079A (pt) Forma de dosagem para o tratamento da diabetes mellitus
CL2017002293A1 (es) Tratamiento de pacientes con diabetes mellitus de tipo 2
BRPI0819323B8 (pt) composição à base de bactéria probiótica em associação com uma prebiótica e uso da mesma na prevenção e/ou tratamento de patologias respiratórias e/ou infecções e no aperfeiçoamento de funcionalidade intestinal
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BR112017006272A2 (pt) composição farmacêutica para tratar colite ulcerativa.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
ECSP21015267A (es) Compuestos de 2,6-diaminopiridina
BR112022022024A2 (pt) Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit
BR112022004401A2 (pt) Tratamento de diabetes mellitus tipo 2
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
UY38067A (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
BRPI0711136A2 (pt) uso de timosina alfa1, isoladamente ou em combinação com ptx3 ou ganciclovir, para o tratamento de infeção por citomegalovìrus
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.